Prognostic significance of Fas (CD95) and TRAIL receptors (DR4/DR5) expression in acute myelogenous leukemia.
We analyzed the clinical significance of the expression of the Fas (CD95) and TNF-related apoptosis-inducing ligand (TRAIL) receptors, the death receptors (DR) 4 and 5, by leukemic blasts in 29 patients with acute myelogenous leukemia (AML). CD95 was positive in 18 patients (62%). The DR4 and DR5 receptors were positive in 20 patients (69%) and 29 (100%), respectively. CD95 positivity was not correlated with cytogenetic abnormalities. Complete remission (CR) rate was not significantly different according to the expression of the CD95 or TRAIL receptors. Relapse-free survival was significantly prolonged in patients with CD95-positive AML cells compared with patients with CD95-negative AML cells (73% versus 38% at 3 years; P = 0.047). TRAIL receptors did not show correlation with other clinical parameters.